Bayer Healthcare backed Metagenomi cuts US IPO valuation target to USD 563 million
New Delhi: Genetic medicines company Metagenomi Technologies said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its initial target range.The company, backed by Moderna and Bayer Healthcare, plans to raise about $93.8 million by selling 6.25 million shares at $15 apiece.That is the lower end of its price...
Login or Register to read the full article
New Delhi: Genetic medicines company Metagenomi Technologies said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its initial target range.
The company, backed by Moderna and Bayer Healthcare, plans to raise about $93.8 million by selling 6.25 million shares at $15 apiece.
That is the lower end of its price range of $15-$17 per share. At $17 per share, Metagenomi would have had a market value of $638 million.
Metagenomi, one of a string of healthcare companies that have recently sought to go public, is developing therapies for genetic diseases like hemophilia A.
All of its revenue has been generated from three collaboration agreements, including one with Moderna, and not any product sales. The company is yet to turn a profit.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd